|
Press Releases |
|
|
|
Wednesday, September 8, 2021 |
|
阿诺医药宣布AN2025、AN0025与atezolizumab三联治疗晚期实体瘤1a期临床在美国完成首例患者给药 |
阿诺医药,一家专注于肿瘤治疗领域的创新型全球生物制药公司,今日宣布其口服泛PI3K抑制剂buparlisib(AN2025)、口服EP4拮抗剂(AN0025)与PD-L1抑制剂atezolizumab(阿替利珠单抗)三联疗法在晚期/转移性实体瘤患者中开展的Ia期临床试验已于美国成功完成首例患者给药。 more info >> |
|
阿諾醫藥宣佈AN2025、AN0025與atezolizumab三聯治療晚期實體瘤1a期臨床在美國完成首例患者給藥 |
阿諾醫藥,一家專注於腫瘤治療領域的創新型全球生物製藥公司,今日宣佈其口服泛PI3K抑制劑buparlisib(AN2025)、口服EP4拮抗劑(AN0025)與PD-L1抑制劑atezolizumab(阿替利珠單抗)三聯療法在晚期/轉移性實體瘤患者中開展的Ia期臨床試驗已于美國成功完成首例患者給藥。 more info >> |
|
Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors |
Adlai Nortye, a global biopharmaceutical company focused on developing innovative oncology drugs, today announced that the first patient has been dosed in the Phase Ia clinical trial in the U.S. to evaluate the triple combination of AN2025 (buparlisib, oral pan-PI3K inhibitor), AN0025 (oral EP4 antagonist) and atezolizumab (PD-L1 inhibitor) in patients with locally advanced/metastatic tumors. more info >> |
|
Thursday, July 15, 2021 |
|
Adlai Nortye Raises $100 Million in Series D Financing, Co-led by SDIC Fund Management and Tigermed, participated by Legend Star, WuXi Biologics Healthcare Ventures |
Adlai Nortye Ltd. (hereinafter referred to as "Adlai Nortye"), a global biopharmaceutical company focused on developing innovative oncology drugs, today announced the completion of $100 million Series D financing round. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Legend Capital Portfolio Company Qunabox Group Lists on the Main Board of the HKEX Successfully
May 29, 2024 11:38: JST
|
|
|
KE Holdings: Capitalizing on Growth in Home Renovation and Furnishing Business and Rental Markets
May 29, 2024 11:10 HKT/SGT
|
|
|
Japanese Consortium Achieves World's First Demonstration of 5G Communication from Altitude of 4km Using 38GHz Band
May 29, 2024 11:44 JST
|
|
|
Legend Capital Portfolio Company Qunabox Group Lists on the Main Board of the HKEX Successfully
May 29, 2024 10:38 HKT/SGT
|
|
|
Hitachi High-Tech Launches the SU3900SE and SU3800SE Series High-Resolution Schottky Field Emission Scanning Electron Microscopes Allowing Observation of Large and Heavy Samples at the Nano Level
May 29, 2024 11:30 JST
|
|
|
Celonis and NEC begin Proof of Concept Integrating Generative AI and Process Intelligence
May 28, 2024 20:20 JST
|
|
|
Genetec's Consistent Performance Delivers Higher Overall Margins in Q4FY2024
May 28, 2024 19:18 HKT/SGT
|
|
|
第四范式发布2024年第一季度业务表现
May 28, 2024 19:09 HKT/SGT
|
|
|
第四範式發佈2024年第一季度業務表現
May 28, 2024 19:00 HKT/SGT
|
|
|
Fourth Paradigm Announces Business Performance For The First Quarter Ended March 31 2024
May 28, 2024 18:00 HKT/SGT
|
|
|
BioMed X Institute and Boehringer Ingelheim Successfully Complete Schizophrenia Research Project
May 28, 2024 18:00 HKT/SGT
|
|
|
MUFG退休金管理及市场服务香港办公室举行开幕式 为拓展区内退休金市场奠定基础
May 28, 2024 17:00 HKT/SGT
|
|
|
MUFG退休金管理及市場服務香港辦公室舉行開幕式 為拓展區內退休金市場奠定基礎
May 28, 2024 16:51 HKT/SGT
|
|
|
MUFG Pension & Market Services Inaugurates Hong Kong Office, Sets the Stage for Expansion into the Region's Pension Market
May 28, 2024 16:35 HKT/SGT
|
|
|
CR Pharmaceutical Armed with Leading Advantages Releases Growth Potential and Achieves High-quality Sustainable Development
May 28, 2024 16:28 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|